Literature DB >> 12637980

The CAG repeat polymorphism in the androgen receptor gene modulates body fat mass and serum concentrations of leptin and insulin in men.

M Zitzmann1, J Gromoll, A von Eckardstein, E Nieschlag.   

Abstract

AIMS/HYPOTHESIS: The relationship of androgens to the metabolic syndrome has not been resolved. The polymorphic number of CAG repeats within the androgen receptor gene is inversely associated with the transcriptional activity of target genes. This polymorphism might thus influence testosterone effects on body fat content and serum concentrations of leptin and insulin. The direct and indirect role of androgens within the metabolic syndrome should become clearer if this genetically determined effector is taken into account.
METHODS: The hypothesis was investigated in a cross-sectional study involving 106 healthy 20-50 year old males.
RESULTS: Multiple regression models showed a positive independent correlation of the CAG repeat number with body fat content, leptin and insulin (partial r=0.39, 0.36 and 0.28, p<0.001, p<0.001 and p=0.006, respectively). Factor analysis yielded a five-dimensional model: two dimensions were influenced by the androgen receptor polymorphism, namely "body composition" which consisted of leptin, body fat mass, insulin, the number of CAG repeats (positive loadings) and physical activity (negative loading), and "lipid profile" which comprised low density lipoprotein cholesterol, cigarette smoking, triglycerides (positive loadings) as well as high density lipoprotein cholesterol and number of CAG repeats (negative loadings). CONCLUSIONS/
INTERPRETATION: A low number of CAG repeats were independently associated with protective parameters (low body fat mass and plasma insulin) as well as with adverse parameters (low high density lipoprotein cholesterol concentrations). This suggests that the pivotal role of this polymorphism in modulating androgen effects on cardiovascular risk factors is of a complex nature and implies that its clinical impact, similar to that of androgens, is dependent on exogenous cofactors.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12637980     DOI: 10.1007/s00125-002-0980-9

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  40 in total

1.  Androgens and vascular function.

Authors:  M Zitzmann; E Nieschlag
Journal:  J Endocrinol Invest       Date:  2003-08       Impact factor: 4.256

Review 2.  [Therapy of male hypogonadism].

Authors:  M Zitzmann
Journal:  Internist (Berl)       Date:  2008-05       Impact factor: 0.743

3.  Clustering of leptin and physical activity with components of metabolic syndrome in Iranian population: an exploratory factor analysis.

Authors:  Alireza Esteghamati; Ali Zandieh; Omid Khalilzadeh; Afsaneh Morteza; Alipasha Meysamie; Manouchehr Nakhjavani; Mohammad Mehdi Gouya
Journal:  Endocrine       Date:  2010-07-11       Impact factor: 3.633

4.  Androgen receptor gene and sex-specific Alzheimer's disease.

Authors:  Raffaele Ferrari; Saad Dawoodi; Merrill Raju; Avinash Thumma; Linda S Hynan; Shirin Hejazi Maasumi; Joan S Reisch; Sid O'Bryant; Marjorie Jenkins; Robert Barber; Parastoo Momeni
Journal:  Neurobiol Aging       Date:  2013-03-29       Impact factor: 4.673

Review 5.  The role of androgens in metabolism, obesity, and diabetes in males and females.

Authors:  Guadalupe Navarro; Camille Allard; Weiwei Xu; Franck Mauvais-Jarvis
Journal:  Obesity (Silver Spring)       Date:  2015-03-06       Impact factor: 5.002

Review 6.  [Hypogonadism in the elderly man. Reliable diagnosis and therapy].

Authors:  M Zitzmann; E Nieschlag
Journal:  Internist (Berl)       Date:  2003-10       Impact factor: 0.743

Review 7.  Androgen replacement therapy: present and future.

Authors:  Louis J G Gooren; Mathijs C M Bunck
Journal:  Drugs       Date:  2004       Impact factor: 9.546

8.  Differential sensitivity of Pak5, Pak6, and Pak5/Pak6 double-knockout mice to the stimulant effects of amphetamine and exercise-induced alterations in body weight.

Authors:  Melody A Furnari; Michelle L Jobes; Tanya Nekrasova; Audrey Minden; George C Wagner
Journal:  Nutr Neurosci       Date:  2013-11-26       Impact factor: 4.994

9.  Androgen receptor CAG repeat length is not associated with the risk of incident symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial.

Authors:  Alan R Kristal; Douglas K Price; Cathee Till; Jeannette M Schenk; Marian L Neuhouser; Sandy Ockers; Daniel W Lin; Ian M Thompson; William D Figg
Journal:  Prostate       Date:  2010-05-01       Impact factor: 4.104

10.  Salivary testosterone and a trinucleotide (CAG) length polymorphism in the androgen receptor gene predict amygdala reactivity in men.

Authors:  Stephen B Manuck; Anna L Marsland; Janine D Flory; Adam Gorka; Robert E Ferrell; Ahmad R Hariri
Journal:  Psychoneuroendocrinology       Date:  2010-01       Impact factor: 4.905

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.